Yusuf Shamil, Camm A John
Department of Cardiovascular Medicine, St. Georges Hospital Medical School, London, UK.
J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):89-105. doi: 10.1177/107424840300800202.
A relatively novel group of drugs that inhibit the funny current in the sinus node pacemaker cells, the so-called specific bradycardic agents, are likely to play a significant role in the management of a wide range of cardiovascular disorders, including the sinus tachyarrhythmias. This comprehensive review initially provides an insight into these agents, their historical background, and their mechanism of action. It then discusses the differential diagnosis of the sinus tachyarrhythmias (normal sinus tachycardia, inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome, and sinus node reentry tachycardia), elaborates on their pathophysiologic basis, and provides up-to-date evidence-based information on their optimum management. The specific bradycardic agents, by the very nature of their mode of action, may prove ideal therapies for the management of the sinus tachyarrhythmias, and this is explored at every stage.
一类相对新颖的药物可抑制窦房结起搏细胞的起搏电流,即所谓的特异性心动过缓药物,它们可能在包括窦性心动过速在内的多种心血管疾病的治疗中发挥重要作用。这篇综述首先深入介绍了这些药物、其历史背景及作用机制。接着讨论了窦性心动过速的鉴别诊断(正常窦性心动过速、不适当窦性心动过速、体位性直立性心动过速综合征和窦房结折返性心动过速),阐述了其病理生理基础,并提供了关于其最佳治疗的最新循证信息。特异性心动过缓药物因其作用方式的本质特性,可能被证明是治疗窦性心动过速的理想疗法,本文在各个阶段都对此进行了探讨。